Lifecore Biomedical Announces Chief Financial Officer Transition
Lifecore Biomedical (NASDAQ: LFCR) announced a significant leadership change with the appointment of Ryan Lake as the new Chief Financial Officer, effective September 3, 2024. Lake, an experienced CDMO industry financial executive, succeeds John Morberg, who is stepping down to pursue other opportunities. Lake brings valuable experience from his previous role as CFO of Societal CDMO, where he led the company's transition into a dedicated CDMO and played a key role in its strategic growth and eventual acquisition by CoreRx.
CEO Paul Josephs expressed confidence in Lake's ability to drive Lifecore's growth strategy, citing his expertise in investor relations, financial strategy, and experience in navigating complex transactions within the CDMO space. Lake's appointment is seen as a strategic move to enhance Lifecore's position in the CDMO market and drive long-term value for stakeholders.
Lifecore Biomedical (NASDAQ: LFCR) ha annunciato un importante cambiamento nella leadership con la nomina di Ryan Lake come nuovo Chief Financial Officer, con effetto dal 3 settembre 2024. Lake, un esperto dirigente finanziario nel settore CDMO, succede a John Morberg, che si dimette per perseguire altre opportunità. Lake porta con sé un'esperienza preziosa dalla sua precedente posizione di CFO di Societal CDMO, dove ha guidato la transizione dell'azienda verso un CDMO dedicato e ha svolto un ruolo chiave nella sua crescita strategica e nell'acquisizione finale da parte di CoreRx.
Il CEO Paul Josephs ha espresso fiducia nella capacità di Lake di guidare la strategia di crescita di Lifecore, citando la sua esperienza nelle relazioni con gli investitori, nella strategia finanziaria e nella gestione di transazioni complesse nel settore CDMO. La nomina di Lake è vista come una mossa strategica per migliorare la posizione di Lifecore nel mercato CDMO e creare valore a lungo termine per gli stakeholder.
Lifecore Biomedical (NASDAQ: LFCR) anunció un cambio significativo en el liderazgo con el nombramiento de Ryan Lake como nuevo Director Financiero, efectivo a partir del 3 de septiembre de 2024. Lake, un ejecutivo financiero experimentado en la industria de CDMO, sucederá a John Morberg, quien deja su cargo para perseguir otras oportunidades. Lake aporta una valiosa experiencia de su anterior rol como CFO de Societal CDMO, donde lideró la transición de la empresa a un CDMO dedicado y desempeñó un papel clave en su crecimiento estratégico y eventual adquisición por CoreRx.
El CEO Paul Josephs expresó confianza en la capacidad de Lake para impulsar la estrategia de crecimiento de Lifecore, citando su experiencia en relaciones con inversores, estrategia financiera y su experiencia en la realización de transacciones complejas dentro del espacio CDMO. El nombramiento de Lake se considera un movimiento estratégico para mejorar la posición de Lifecore en el mercado de CDMO y generar valor a largo plazo para los interesados.
라이프코어 바이오메디컬 (NASDAQ: LFCR)는 라이언 레이크를 신임 최고재무책임자(CFO)로 임명하며 중요한 리더십 변화를 발표했습니다. 임기는 2024년 9월 3일부터 시작됩니다. 레이크는 CDMO 산업에서 경험이 풍부한 재무 임원으로, 다른 기회를 추구하기 위해 물러나는 존 모르버그를 이어받습니다. 레이크는 소셜 CDMO의 CFO로서의 이전 역할에서 귀중한 경험을 가져오며, 여기서 그는 회사를 전담 CDMO로 전환하고 전략적 성장 및 CoreRx에 의한 최종 인수 과정에서 핵심 역할을 했습니다.
CEO 폴 조셉스는 투자자 관계, 재무 전략 및 CDMO 분야에서 복잡한 거래를 처리한 경험을 언급하며 레이크의 Lifecore 성장 전략을 주도할 수 있는 능력에 대한 신뢰를 표명했습니다. 레이크의 임명은 Lifecore의 CDMO 시장 내 위치를 강화하고 이해관계자에게 장기적인 가치를 제공하기 위한 전략적 결정으로 간주됩니다.
Lifecore Biomedical (NASDAQ: LFCR) a annoncé un changement significatif dans son leadership avec la nomination de Ryan Lake en tant que nouveau Directeur Financier, à compter du 3 septembre 2024. Lake, un cadre financier expérimenté dans l'industrie CDMO, succède à John Morberg, qui se retire pour poursuivre d'autres opportunités. Lake apporte une expérience précieuse de son précédent poste de CFO chez Societal CDMO, où il a dirigé la transition de l'entreprise vers un CDMO dédié et a joué un rôle clé dans sa croissance stratégique et son acquisition finale par CoreRx.
Le PDG Paul Josephs a exprimé sa confiance dans la capacité de Lake à piloter la stratégie de croissance de Lifecore, citant son expertise en relations avec les investisseurs, en stratégie financière et son expérience dans la gestion de transactions complexes dans le domaine des CDMO. La nomination de Lake est considérée comme un mouvement stratégique pour renforcer la position de Lifecore sur le marché CDMO et générer une valeur à long terme pour les parties prenantes.
Lifecore Biomedical (NASDAQ: LFCR) hat einen bedeutenden Führungswechsel mit der Ernennung von Ryan Lake zum neuen Chief Financial Officer angekündigt, der am 3. September 2024 in Kraft tritt. Lake, ein erfahrener Finanzmanager in der CDMO-Branche, tritt die Nachfolge von John Morberg an, der zurücktritt, um andere Möglichkeiten zu verfolgen. Lake bringt wertvolle Erfahrungen aus seiner vorherigen Rolle als CFO von Societal CDMO mit, wo er den Übergang des Unternehmens zu einem spezialisierten CDMO leitete und eine Schlüsselrolle in seinem strategischen Wachstum und der letztendlichen Übernahme durch CoreRx spielte.
CEO Paul Josephs äußerte Vertrauen in Lakes Fähigkeit, Lifecores Wachstumsstrategie voranzutreiben, und nannte dabei seine Expertise in den Bereichen Investor Relations, Finanzstrategie und Erfahrung im Umgang mit komplexen Transaktionen im CDMO-Bereich. Lakes Ernennung wird als strategischer Schritt angesehen, um Lifecores Position im CDMO-Markt zu verbessern und den langfristigen Wert für die Stakeholder zu steigern.
- Appointment of experienced CDMO financial executive Ryan Lake as new CFO
- Lake's proven track record in leading companies through complex transactions and raising capital
- Lake's experience in transitioning companies into dedicated CDMOs aligns with Lifecore's strategy
- Potential for improved investor relations and financial strategy execution
- Departure of current CFO John Morberg, which may cause short-term transitional challenges
Insights
The appointment of Ryan Lake as CFO of Lifecore Biomedical is a strategic move that could potentially benefit the company's financial operations and growth strategy. Lake's extensive experience in the CDMO industry, particularly his role in transitioning Societal CDMO into a dedicated CDMO, aligns well with Lifecore's current position. His track record of raising over
However, it's important to note that executive transitions can sometimes lead to short-term uncertainties. Investors should monitor how smoothly Lake integrates into Lifecore's existing operations and whether his strategies align with the company's current trajectory. The market's reaction to this news will likely be neutral to slightly positive, given Lake's relevant experience, but concrete results will be needed to significantly impact stock performance.
This CFO transition at Lifecore Biomedical reflects a broader trend in the CDMO industry towards specialized expertise. Ryan Lake's appointment signals Lifecore's intent to refine its strategy and potentially expand its market presence. The CDMO market is experiencing significant growth, driven by pharmaceutical companies increasingly outsourcing development and manufacturing.
Lake's experience in corporate rebranding and expanding service offerings at Societal CDMO could be particularly valuable for Lifecore. If he can successfully implement similar strategies, it could lead to an expanded customer base and increased market share. However, the CDMO space is highly competitive and success will depend on Lifecore's ability to differentiate its services and capitalize on emerging opportunities. Investors should watch for any announcements regarding new capabilities or strategic partnerships in the coming months.
Experienced CDMO Industry Financial Executive Ryan Lake Appointed CFO
CHASKA, Minn., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that John Morberg will be stepping down from his position as chief financial officer to pursue other professional opportunities and spend time with his family, effective September 2, 2024. In addition, the Company is pleased to announce that Ryan Lake, an accomplished CDMO financial executive, will succeed Mr. Morberg as CFO beginning September 3, 2024.
“On behalf of the board of directors, along with the entire Lifecore team, I would like to express our gratitude to John for his years of service as the Company’s chief financial officer. During his tenure, he has proven to be an invaluable member of leadership making significant contributions to the Company’s overall success, while also skillfully navigating the organization through numerous complex transactions as it transitioned into a dedicated CDMO,” said Paul Josephs, president and chief executive officer of Lifecore. “We wish John the best in all his future endeavors.”
Mr. Josephs continued, “We are excited to bring Ryan on board at this important time for Lifecore as we work to refine and execute a comprehensive strategy to marry our unique strengths with the significant opportunities in the CDMO space in order to achieve sustained growth. Ryan’s impressive experience uniquely positions him for this role. Not only has he served as a successful public company CFO within the CDMO space, but he has also experienced firsthand the complexities of creating a dedicated CDMO from a larger organization with multiple business arms. These parallels with the Lifecore story equip him with valuable insight and experience that will serve the Company well on our exciting path forward.”
During his career, Mr. Lake has been credited with leading and advising corporations through mergers, acquisitions, spin-offs, recapitalizations, integrations, equity, debt, and stock market transactions. He has raised over
“Our commitment to transparency and value creation has never been stronger,” said Mr. Josephs. “With Ryan joining us, we gain a leader whose exceptional skills in investor relations and financial strategy will be instrumental in steering Lifecore toward its next chapter of growth. Ryan’s proven ability to communicate effectively with stakeholders and manage complex financial operations will enhance our commitment to delivering long-term value.”
As CFO of Societal CDMO (formerly Recro Pharma, Inc.), Mr. Lake played an instrumental role in strategically transitioning the company into a dedicated CDMO through the spin-off of the organization’s therapeutic pipeline development arm. Following this transaction, he was intimately involved in a comprehensive corporate rebranding and the creation and execution of a strategic plan to grow the company, adding critical new capabilities to its service offerings, and in turn expanding its customer base. Mr. Lake also led efforts to strengthen the company’s financial position, including leveraging non-core assets, and built visibility with key financial community stakeholders. These efforts helped contribute to the successful acquisition of Societal CDMO by CoreRx, another CDMO, in April 2024.
Prior to his time with Societal, Mr. Lake served as CFO and vice president of finance of Aspire Bariatrics, Inc., a privately held, commercial-stage, medical device company. From 2012 to 2015, he held executive management and senior finance positions, including director of the natural materials division, controller and senior director of finance, at DSM Biomedical (successor to Kensey Nash after its acquisition in 2012), a division of Royal DSM (listed on Euronext Amsterdam), a global science-based company active in health, nutrition and materials. From 2002 to 2012, Mr. Lake served in various senior financial positions, most notably interim CFO and senior director of finance, with Kensey Nash Corporation, a Nasdaq-listed, medical device company. Earlier in his career, Mr. Lake worked at Deloitte & Touche, LLP.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the Company, visit Lifecore’s website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our preliminary estimates of historical financial data for the Historical Periods, current operating and financial expectations in light of historical results, anticipated capacity and utilization, anticipated liquidity, and anticipated future customer relationships usage are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors among others, as the Company’s ability to successfully enact its business strategies, including with respect to installation, capacity generation and its ability to attract demand for its services, and its ability expand its relationship with its existing customers or attract new customers; the impact of inflation on the Company’s business and financial condition;; changes in business conditions and general economic conditions both domestically and globally including rising interest rates and fluctuation in foreign currency exchange rates; the Company’s ability to access to capital to fund its business strategies; and other risk factors set forth from time to time in the Company’s SEC filings, including, but not limited to, the Annual Report on Form 10-K for the year ended May 26, 2024 (the “2024 10-K”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the Securities and Exchange Commission, including the risk factors contained in the 2024 10-K. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
FAQ
When will Ryan Lake assume the role of CFO at Lifecore Biomedical (LFCR)?
What is Ryan Lake's background in the CDMO industry?
How much capital has Ryan Lake raised in his career?
When is John Morberg stepping down as CFO of Lifecore Biomedical (LFCR)?
